A very important paper by Young-II Kim et al. 1 was published recently in Endoscopy . The authors found that the Glasgow-Blatchford score (GBS) was inferior to the Rockall score in predicting the need for urgent hemostatic intervention for tumor-associated upper gastrointestinal bleeding (UGIB), leading to poor performance (area under the receiver operating characteristic curve [AUROC] 0.56). This study is crucial for patient risk stratification for UGIB during the COVID-19 pandemic, and we would like to draw your attention toward it.
The COVID-19 pandemic has severely affected the practice of gastrointestinal (GI) endoscopy worldwide because upper GI endoscopy has been recognized as an aerosol-generating procedure that increases the risk of COVID-19 infection 2 . Thus, the endoscopic management of patients with UGIB now presents a dilemma. The pre-endoscopy risk scores, such as GBS, are based on pre-pandemic research and have not been validated by large-scale studies during the COVID-19 pandemic. A recent case series 3 has shown that six UGIB patients with COVID and GBS > 7 did not require endoscopy and were conservatively managed, which did not accord with the relevant European Society for Gastrointestinal Endoscopy (ESGE) guideline 4 . The latter recommends only that patients with a GBS score of 0 – 1 do not require endoscopy. Thus, the performance of the GBS has seemed to be especially limited during the COVID-19 pandemic 3 . According to Laursen et al. 5 , the low-risk threshold for defining UGIB patients who do not require inpatient endoscopy and hospitalization could be increased to GBS < 3.
In conclusion, the COVID-19 pandemic remains a worldwide challenge, and its impact on GI endoscopy and UGIB detection could be increasingly significant. Raising the GBS threshold or developing a new and accurate risk score before endoscopy in UGIB patients will be critical in the prevention of a UGIB healthcare crisis. We hope a more rigorous study will be conducted in the near future.
Footnotes
Competing interests The authors declare no conflicts of interest.
References
- 1.Kim Y I, Choi I J, Lee J Y et al. Comparison of the performance of risk scoring systems for tumor bleeding in patients with inoperable gastric cancer. Endoscopy. 2020;52:359–367. doi: 10.1055/a-1114-6000. [DOI] [PubMed] [Google Scholar]
- 2.Gralnek I M, Hassan C, Beilenhoff U et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. Endoscopy. 2020;52:483–490. doi: 10.1055/a-1155-6229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Cavaliere K, Levine C, Wander P et al. Management of upper GI bleeding in patients with COVID-19 pneumonia. Gastrointest Endosc. 2020;92:454–455. doi: 10.1016/j.gie.2020.04.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Gralnek I M, Dumonceau J M, Kuipers E J et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47:a1–a46. doi: 10.1055/s-0034-1393172. [DOI] [PubMed] [Google Scholar]
- 5.Laursen S B, Gralnek I M, Stanley A J. Raising the threshold for hospital admission and endoscopy in upper gastrointestinal bleeding during the COVID-19 pandemic. Endoscopy. 2020;52:930–931. doi: 10.1055/a-1202-1374. [DOI] [PMC free article] [PubMed] [Google Scholar]